- Home
- Reports Store
- Medical Devices
Point-of-Care Diagnostics Market
Customise your request
Need this report to answer something it does not cover? Tell us the decision you are facing and we will scope the work — or point you to a study that already answers it.
info@cortexmeridian.com+971 56 483 5090Report Scope
| Report ID / SKU | CM-MD-0003 |
|---|---|
| Report Code | CM-MD-P1-1003 |
| Report Type | Market Analysis & Forecast |
| Base Year | 2025 |
| Historical Period | 2021–2025 |
| Forecast Period | 2026–2035 |
| Geographic Scope | Global |
| Global Coverage | Yes |
| Regions Covered | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Countries Covered | US; Canada; Mexico; UK; Germany; France; Italy; Spain; Netherlands; Switzerland; China; India; Japan; South Korea; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa (20 countries) |
| Market Size Unit | USD Billion |
| Volume Unit | Tests / Cartridges / Analyzers |
| Report Format | PPT / WORD / EXCEL / PDF |
| Page Count | 180-220 |
| Delivery Timeline | 48 hours |
| Sample Available | Yes |
| Author / Analyst | Cortex Meridian Medical Devices Analyst Team |
| Publish Date | October 2026 |
| Last Updated | 2026-10-06 |
Market Overview & Definition

The Point-of-Care Diagnostics market is estimated by Cortex Meridian Research at USD 21.7 billion in 2025 and is projected to reach approximately USD 32.4 billion by 2035, reflecting a CAGR of 4.1%. The market is being reshaped by the economic value of faster decision-making rather than simply by test decentralization. In emergency, urgent-care, pharmacy and home settings, a test that avoids laboratory delay can reduce repeat visits, shorten time to treatment and improve patient routing. This is creating room for higher-value cartridge-based molecular systems alongside traditional low-cost rapid tests.
The strongest growth opportunities are in settings where speed and clinical sensitivity both matter. Molecular point-of-care testing, cardiac markers, coagulation and blood-gas analysis fit this profile particularly well. By contrast, commoditized lateral-flow categories remain highly price sensitive and face strong competition from regional and private-label suppliers.
Roche’s continued expansion of the cobas liat menu and Cepheid’s next-generation GeneXpert strategy show that major diagnostics companies view decentralized molecular testing as a long-term platform opportunity. Their advantage is not just analytical performance, but the ability to build recurring cartridge revenue around installed systems. The market is therefore likely to shift progressively toward connected, menu-rich platforms that can serve multiple clinical pathways rather than single-test devices.
Report Description
The Point-of-Care Diagnostics Market covers revenue generated from the defined medical-device products, related consumables and software/services where directly attached to the device workflow. The report excludes unrelated pharmaceuticals and stand-alone healthcare services. The scope is designed for manufacturers, suppliers, distributors, hospitals, diagnostic providers, investors and strategy teams evaluating demand, technology shifts, pricing and competitive opportunity.
Overall Market Dynamics
Drivers
Need for rapid clinical decisions, decentralization of care, home testing, emergency/ambulatory workflows and improved connectivity.
Restraints / Risks
Variable reimbursement, quality-control requirements outside central labs, operator training and price competition in rapid tests.
Opportunities
POC molecular testing, telehealth-enabled diagnostics, multiplex respiratory panels, home chronic-disease monitoring and emerging-market penetration.
Strategic themes
AI/connectivity, workflow efficiency, reimbursement, regulatory approvals, recurring consumables/service revenue, and regional access expansion.
Segmentation & Scope

By product: infectious disease, glucose, cardiac markers, blood gas/electrolytes, coagulation, pregnancy/fertility, urinalysis; by platform: lateral flow, cartridge, biosensor, molecular; by setting: hospitals, clinics, home, pharmacies, assisted living; by geography.
Regional & Country Outlook

COUNTRY CHAPTER COVERAGE 1. US: POC market size; CLIA-waived testing; urgent care/pharmacy/home testing; reimbursement; molecular POC; Abbott/Roche/Cepheid competition. 2. Canada: decentralized testing; rural access; hospital POC; reimbursement; infectious disease and glucose testing. 3. UK: NHS near-patient testing; emergency/primary care use; POC governance; reimbursement; molecular POC. 4. Germany: hospital and physician-office testing; reimbursement; blood gas and cardiac marker use; molecular POC. 5. France: hospital POC; pharmacy/home testing; infectious disease; reimbursement; procurement. 6. Italy: hospital and emergency POC; regional adoption; glucose/blood gas; procurement. 7. Spain: primary care and hospital POC; infectious disease; reimbursement; decentralized workflows. 8. Netherlands: connected POC; primary care; anticoagulation and infectious disease testing; digital integration. 9. Switzerland: premium POC systems; hospital/clinic adoption; molecular and cardiac testing. 10. China: hospital POC expansion; domestic suppliers; infectious disease; glucose; pricing and procurement. 11. India: low-cost rapid tests; glucose; cardiac markers; infectious disease; rural and pharmacy channels. 12. Japan: hospital POC; aging-related testing; compact analyzers; reimbursement; quality standards. 13. South Korea: hospital and clinic POC; digital connectivity; molecular and cardiac testing. 14. Australia: rural/remote POC; primary care; infectious disease; reimbursement; indigenous health access. 15. Brazil: rapid testing; emergency care; public/private adoption; infectious disease; distributor economics. 16. Argentina: hospital POC; rapid tests; import dependence; pricing and access. 17. Saudi Arabia: hospital modernization; emergency POC; diabetes testing; tenders; localization. 18. UAE: private hospital POC; premium molecular systems; emergency and outpatient adoption. 19. South Africa: HIV/TB and infectious disease POC; rural access; public procurement; glucose testing.
Competitive Landscape & Companies Covered
Abbott; Roche; Danaher; Siemens Healthineers; BD; bioMérieux; QIAGEN; QuidelOrtho; Nova Biomedical; Werfen
Pricing & Ecosystem
Pricing, Cost & Revenue Intelligence
Pricing intelligence benchmarks capital-system ASPs, disposable/consumable pricing, procedure-linked device pricing, service contracts, software subscriptions and regional tender dynamics where applicable. The model distinguishes capital equipment from recurring revenue and evaluates discounting, bundling, distributor margins, reimbursement sensitivity and premium technology price realization.
Value Chain & Ecosystem Analysis
The ecosystem maps component and sensor suppliers, materials vendors, device OEMs, software/AI partners, contract manufacturers, sterilization and packaging providers, distributors, hospitals/diagnostic laboratories/ASCs, clinicians, payers and regulators. The analysis identifies control points in the value chain, recurring-revenue pools, channel dependencies and partnership opportunities.
Opportunity & White-Space Analysis
A weighted opportunity model scores product segments, technologies, countries, end users and accounts using growth, market size, clinical adoption, reimbursement, competitive intensity, regulatory accessibility and margin potential. Priority white spaces include POC molecular testing, telehealth-enabled diagnostics, multiplex respiratory panels, home chronic-disease monitoring and emerging-market penetration.
Executive Summary
Cortex Meridian Research estimates the Point-of-Care Diagnostics market at USD 21.7 billion in 2025, rising to about USD 32.4 billion by 2035 at a CAGR of 4.1%. Growth is driven by the clinical and economic benefit of shortening the diagnostic cycle, particularly in emergency care, urgent care, pharmacies and home settings.
The most attractive opportunity is not generic rapid testing but higher-value decentralized platforms that combine speed with laboratory-grade sensitivity. Roche’s cobas liat expansion and Cepheid’s GeneXpert roadmap illustrate how the market is moving toward recurring cartridge-based business models. Vendors that can broaden menus, integrate connectivity and support decentralized quality control are likely to capture disproportionate value, while basic rapid-test categories will remain exposed to pricing pressure.
Key Takeaways
- 2025 Cortex normalized estimate: USD 21.7 billion
- 2035 normalized outlook: USD 32.4 billion
- Normalized 2025–2035 CAGR: 4.1%
- Key growth drivers: Need for rapid clinical decisions, decentralization of care, home testing, emergency/ambulatory workflows and improved connectivity.
- Priority opportunity areas: POC molecular testing, telehealth-enabled diagnostics, multiplex respiratory panels, home chronic-disease monitoring and emerging-market penetration.
- Primary competitive set: Abbott; Roche; Danaher; Siemens Healthineers; BD; bioMérieux; QIAGEN; QuidelOrtho; Nova Biomedical; Werfen
Table of Contents
List of Tables
- Global market value, 2021–2035
- Market by product/device type
- Market by technology
- Market by application/procedure
- Market by end user
- Market by region
- Country market sizing
- Installed base/procedure/test indicators
- ASP/pricing benchmark
- Company/product benchmark
- Opportunity attractiveness scoring
List of Figures
- Market size and CAGR outlook
- Segment attractiveness matrix
- Technology adoption curve
- Regional opportunity heat map
- Competitive positioning matrix
- Value-chain ecosystem map
- Pricing/revenue model
- Opportunity prioritization matrix
Research Methodology
Methodology
Cortex Meridian Research applies a triangulated market-sizing framework combining company disclosures, regulatory databases, procedure/test volumes, installed-base indicators, shipment and utilization data, hospital and laboratory purchasing patterns, reimbursement signals, product approvals, and primary research. Public market benchmarks are used only as external calibration points; Cortex values are normalized to the defined scope and forecast period. Forecasts consider technology adoption, procedure/test growth, replacement cycles, pricing, reimbursement, regulatory changes, and regional healthcare investment.
Data Sources & Validation
Company annual reports and investor materials; FDA, EMA and other regulatory databases; WHO and national health agencies; peer-reviewed clinical literature; procurement and reimbursement sources; hospital/laboratory statistics; trade and shipment indicators; company product portfolios; primary interviews; and public market benchmarks used for calibration.
FAQ — Buyer Questions
Q: What is the 2025 global Point-of-Care Diagnostics market size? A: Cortex Meridian Research estimates it at approximately USD 21.7 billion.
Q: What is the 2035 market outlook? A: The normalized outlook is approximately USD 32.4 billion, based on a 4.1% CAGR assumption.
Q: What are the major growth drivers? A: Need for rapid clinical decisions, decentralization of care, home testing, emergency/ambulatory workflows and improved connectivity.
Q: Which opportunities should suppliers prioritize? A: POC molecular testing, telehealth-enabled diagnostics, multiplex respiratory panels, home chronic-disease monitoring and emerging-market penetration.
Customization Options
Customization can include country-level sizing, procedure/test volumes, installed base, ASP benchmarking, hospital/lab account mapping, competitor benchmarking, product pipeline analysis, regulatory and reimbursement tracking, KOL mapping, distributor/channel assessment, and opportunity prioritization.
Need something this report does not cover?
Describe the decision you are facing. If a published study already answers it we will point you there; if not, we will scope the work and come back with timeline and cost.
CM-MD-0003 · CM-MD-P1-1003 · 180-220 pages · Published October 2026 · Cortex Meridian Medical Devices Analyst Team
